Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817901) titled 'Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Yonsei University
Condition:
Unresectable or Metastatic Melanoma
Intervention:
Drug: Pembrolizumab and Irinotecan
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: November 1, 2026
Target Sample Size: 46
To...